Orbimed Advisors Llc - Sep 20, 2021 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
Director, 10%+ Owner
Signature
OrbiMed Advisors LLC, By: /s/ Douglas Coon, Chief Compliance Officer
Stock symbol
CRVS
Transactions as of
Sep 20, 2021
Transactions value $
-$6,757,732
Form type
4
Date filed
9/22/2021, 05:27 PM
Previous filing
Sep 21, 2021
Next filing
Oct 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRVS Common Stock, $0.0001 par value Sale -$6.76M -1.11M -13.78% $6.09 6.94M Sep 20, 2021 See Footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is a weighted average price. These shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $6.01 to $6.09. The Reporting Persons undertake to provide Corvus Pharmaceuticals, Inc., any security holder of Corvus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. OrbiMed Advisors and GP V exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI V.
F3 This report is being jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Peter Thompson ("Thompson"), an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Thompson is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.